How to buy Nephros stock

Nephros, Inc is a medical instruments & supplies business based in the US. Nephros shares (NEPH) are listed on the NASDAQ and all prices are listed in US Dollars. Nephros employs 27 staff and has a trailing 12-month revenue of around 0.00.

Nephros share price

Use our graph to track the performance of NEPH stocks over time.

Nephros shares at a glance

• Key figures

Information last updated 2021-04-23.

52-week range	$5.08 - $10.00
50-day moving average	$7.52
200-day moving average	$7.34
Wall St. target price	$13.83
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-0.52

Buy Nephros shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Nephros stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Nephros, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Nephros financials

Revenue TTM	$8.6 million
Gross profit TTM	$4.9 million
Return on assets TTM	-18.68%
Return on equity TTM	-38.91%
Profit margin	-55.67%
Book value	$1.27
Market capitalisation	$76.1 million

TTM: trailing 12 months

Shorting Nephros shares

There are currently 10,716 Nephros shares held short by investors – that's known as Nephros's "short interest". This figure is 19.6% up from 8,963 last month.

There are a few different ways that this level of interest in shorting Nephros shares can be evaluated.

Nephros's "short interest ratio" (SIR)

Nephros's "short interest ratio" (SIR) is the quantity of Nephros shares currently shorted divided by the average quantity of Nephros shares traded daily (recently around 14100). Nephros's SIR currently stands at 0.76. In other words for every 100,000 Nephros shares traded daily on the market, roughly 760 shares are currently held short.

However Nephros's short interest can also be evaluated against the total number of Nephros shares, or, against the total number of tradable Nephros shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Nephros's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Nephros shares in existence, roughly 0 shares are currently held short) or 0.0018% of the tradable shares (for every 100,000 tradable Nephros shares, roughly 2 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Nephros.

Find out more about how you can short Nephros stock.

Nephros share dividends

We're not expecting Nephros to pay a dividend over the next 12 months.

Have Nephros's shares ever split?

Nephros's shares were split on a 1:9 basis on 9 July 2019. So if you had owned 9 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Nephros shares – just the quantity. However, indirectly, the new 800% higher share price could have impacted the market appetite for Nephros shares which in turn could have impacted Nephros's share price.

Nephros share price volatility

Over the last 12 months, Nephros's shares have ranged in value from as little as $5.0813 up to $10. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Nephros's is 1.3458. This would suggest that Nephros's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Nephros overview

Nephros, Inc. , a commercial-stage company, develops and sells water solutions to the medical and commercial markets in the United States. The company operates through three segments: Water Filtration, Pathogen Detection, and Renal Products. Its ultrafilters are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities. The company develops and sells water testing systems to provide actionable data on waterborne pathogens; and medical device products for patients with renal disease, including a 2nd generation hemodiafiltration system for the treatment of patients with end stage renal disease. Nephros, Inc. was incorporated in 1997 and is headquartered in South Orange, New Jersey.

Frequently asked questions

• What percentage of Nephros is owned by insiders or institutions?

  Currently 12.479% of Nephros shares are held by insiders and 53.231% by institutions.

• How many people work for Nephros?

  Latest data suggests 27 work at Nephros.

• When does the fiscal year end for Nephros?

  Nephros's fiscal year ends in December.

• Where is Nephros based?

  Nephros's address is: 380 Lackawanna Place, South Orange, NJ, United States, 07079

• What is Nephros's ISIN number?

  Nephros's international securities identification number is: US6406714005

• What is Nephros's CUSIP number?

  Nephros's Committee on Uniform Securities Identification Procedures number is: 640671103